Preparing for commercialization?
Discuss commercial readiness, launch timing and organizational decisions with PharmaKonsult.
Launch Planning
Biotechnology Commercial Launch Roadmap
An illustrative 36-month framework for the commercial decisions that shape a first U.S. biotech launch.
An Illustrative Planning Framework
Emerging biotechnology companies preparing for a first U.S. commercial launch need a shared view of what must be decided long before approval. This roadmap organizes typical strategic questions by stage.
Illustrative planning framework; actual timing depends on the company, therapy, indication and market.
Use with the Commercial Readiness Framework, the readiness checklist, and first commercial launch advisory.
Launch Timeline Stages
36+ months
Market learning begins
- Challenge prevalence versus diagnosed opportunity
- Map patient journey and Centers of Excellence
- Identify evidence gaps that affect physicians and payers
- Begin commercial thinking inside development decisions
24–36 months
Strategy takes shape
- Clarify independent commercialization versus partnership options
- Define preliminary commercial model and investment range
- Sequence Medical Affairs and access evidence needs
- Establish board visibility on commercial risk
18–24 months
Capabilities and leadership
- Determine when senior commercial leadership is required
- Design organization around the market—not convention
- Advance market access and patient-support concepts
- Pressure-test forecasts and adoption assumptions
12–18 months
Operational readiness
- Hire and onboard critical commercial roles
- Integrate Commercial, Medical Affairs and Market Access plans
- Define launch governance, milestones and owners
- Conduct a formal launch readiness assessment
6–12 months
Execution intensification
- Finalize field and account models
- Stand up patient services and specialty pharmacy pathways
- Complete training, analytics and operational systems
- Revisit the five greatest launch risks with leadership
0–6 months
Launch readiness confirmation
- Confirm access pathways and site readiness where relevant
- Align messaging with scientific and access reality
- Stress-test cross-functional dependencies
- Ensure board and investors understand residual risk
Launch
Availability meets execution
- Monitor initiation barriers in real time
- Protect focus on Centers of Excellence and referral networks
- Escalate access and operational failures quickly
- Keep leadership aligned on leading indicators—not vanity metrics
Post-launch
Learn and adapt
- Compare assumptions to early real-world performance
- Refine organization and investment against market reality
- Strengthen evidence and access based on friction points
- Capture institutional learning for the next indication or asset
How to Use This Roadmap
Do not treat stages as universal rules. Begin with the decisions that reduce optionality if delayed. For rare disease and concentrated specialty markets, organizational scale may stay deliberately focused while evidence, Centers of Excellence engagement and access preparation still require early attention.
